Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 :
A. Selectivity of agonists
B. Selectivity of antagonists
C. Transducer pathway of response effectuation
D. Organ selective location
by

1 Answer

Answer :

C. Transducer pathway of response effectuation
by

Related questions

Which of the following is not the basis for subclassifying β adrenergic receptors into β 1 and β 2: A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β 1 and β 2: A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Adrenergic β2 agonists produce muscle tremor by: A. Facilitating neuromuscular transmission B. Incomplete fusion of contractile response of individual fibres C. Enhanced firing of muscle spindles D. Both (b) and (c) are correct

Description : Adrenergic β2 agonists produce muscle tremor by: A. Facilitating neuromuscular transmission B. Incomplete fusion of contractile response of individual fibres C. Enhanced firing of muscle spindles D. Both (b) and (c) are correct

Last Answer : D. Both (b) and (c) are correct

Adrenergic β2 agonists produce muscle tremor by: A. Facilitating neuromuscular transmission B. Incomplete fusion of contractile response of individual fibres C. Enhanced firing of muscle spindles D. Both (b) and (c) are correct

Description : Adrenergic β2 agonists produce muscle tremor by: A. Facilitating neuromuscular transmission B. Incomplete fusion of contractile response of individual fibres C. Enhanced firing of muscle spindles D. Both (b) and (c) are correct

Last Answer : D. Both (b) and (c) are correct

Leukotriene antagonists are used in bronchial asthma: A. For terminating acute attacks B. As monotherapy in place of β2 agonists C. As adjuvants to β2 agonists for avoiding corticosteroids D. As nebulized powder in refractory cases

Description : Leukotriene antagonists are used in bronchial asthma: A. For terminating acute attacks B. As monotherapy in place of β2 agonists C. As adjuvants to β2 agonists for avoiding corticosteroids D. As nebulized powder in refractory cases

Last Answer : C. As adjuvants to β2 agonists for avoiding corticosteroids

Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Description : Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Last Answer : Answer : A

Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Description : Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Last Answer : Answer : D

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Description : Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Last Answer : A. Continuous use of agonists

Receptors perform the following function/functions: A. Ligand recognition B. Signal transduction C. Both ligand recognition and signal transduction D. Disposal of agonists and antagonists

Description : Receptors perform the following function/functions: A. Ligand recognition B. Signal transduction C. Both ligand recognition and signal transduction D. Disposal of agonists and antagonists

Last Answer : C. Both ligand recognition and signal transduction

Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Description : Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Last Answer : C. Withdrawal is less likely to exacerbate angina pectoris

The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Description : The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Last Answer : B. It is a rectangular hyperbola

Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Description : Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Last Answer : A. More potent β adrenergic blocking than α blocking activity

Insulin release from pancreatic β cells is augmented by the following except: A. Ketone bodies B. Glucagon C. Vagal stimulation D. Alfa adrenergic agonists

Description : Insulin release from pancreatic β cells is augmented by the following except: A. Ketone bodies B. Glucagon C. Vagal stimulation D. Alfa adrenergic agonists

Last Answer : D. Alfa adrenergic agonist

Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers

Description : Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers

Last Answer : D. Ocular β adrenergic blockers

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

In comparison to inhaled β 2 adrenergic agonists, the inhaled anticholinergics: A. Are more effective in bronchial asthma B. Are better suited for control of an acute attack of asthma C. Produce slower response in bronchial asthma D. Produce little benefit in chronic obstructive lung disease

Description : In comparison to inhaled β 2 adrenergic agonists, the inhaled anticholinergics: A. Are more effective in bronchial asthma B. Are better suited for control of an acute attack of asthma C. Produce slower response in bronchial asthma D. Produce little benefit in chronic obstructive lung disease

Last Answer : C. Produce slower response in bronchial asthma

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Description : Down regulation of receptors can occur as a consequence of: A. Continuous use of agonists B. Continuous use of antagonists C. Chronic use of CNS depressants D. Denervation

Last Answer : A. Continuous use of agonists

Receptors perform the following function/functions: A. Ligand recognition B. Signal transduction C. Both ligand recognition and signal transduction D. Disposal of agonists and antagonists

Description : Receptors perform the following function/functions: A. Ligand recognition B. Signal transduction C. Both ligand recognition and signal transduction D. Disposal of agonists and antagonists

Last Answer : C. Both ligand recognition and signal transduction

Adrenergic β 1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Description : Adrenergic β 1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity

Last Answer : C. Withdrawal is less likely to exacerbate angina pectoris

The receptor transduction mechanism with the fastest time-course of response effectuation is: A. Adenylyl cyclase-cyclic AMP pathway B. Phospholipase C-IP3: DAG pathway C. Intrinsic ion channel operation D. Protein synthesis modulation

Description : The receptor transduction mechanism with the fastest time-course of response effectuation is: A. Adenylyl cyclase-cyclic AMP pathway B. Phospholipase C-IP3: DAG pathway C. Intrinsic ion channel operation D. Protein synthesis modulation

Last Answer : C. Intrinsic ion channel operation

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Description : The following statement is not true of log dose-response curve: A. It is almost linear except at the ends B. It is a rectangular hyperbola C. It facilitates comparison of different agonists D. It can help in discriminating between competitive and noncompetitive antagonists

Last Answer : B. It is a rectangular hyperbola

The basis for use of β-adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Description : The basis for use of β-adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Last Answer : B. They counteract deleterious effect of sympathetic overactivity on the myocardium

The basis for use of β -adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Description : The basis for use of β -adrenergic blockers in congestive heart failure (CHF) is: A. They exert positive inotropic effect in CHF B. They counteract deleterious effect of sympathetic overactivity on the myocardium C. They exert antiischaemic effect on the heart D. They prevent cardiac arrhythmias

Last Answer : B. They counteract deleterious effect of sympathetic overactivity on the myocardium

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Select the correct statement about salmeterol: A. It is a long acting selective β2 agonist bronchodilator B. It is a bronchodilator with anti-inflammatory property C. It is a β blocker that can be safely given to asthmatics D. It is an antihistaminic with mast cell stabilizing property

Description : Select the correct statement about salmeterol: A. It is a long acting selective β2 agonist bronchodilator B. It is a bronchodilator with anti-inflammatory property C. It is a β blocker that can be safely given to asthmatics D. It is an antihistaminic with mast cell stabilizing property

Last Answer : A. It is a long acting selective β2 agonist bronchodilator

Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers

Description : Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers

Last Answer : D. Ocular β adrenergic blockers

The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β 1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

The equivalent production rules corresponding to the production rules S→Sα1|Sα2|β1|β2 is (A) S→β1 | β2, A→α1A | α2A | λ (B) S→β1 | β2 | β1A | β2A, A→α1A | α2A (C) S→β1 | β2, A→α1A | α2A (D) S→β1 | β2 | β1A | β2A, A→α1A | α2A | λ

Description : The equivalent production rules corresponding to the production rules S→Sα1|Sα2|β1|β2 is (A) S→β1 | β2, A→α1A | α2A | λ (B) S→β1 | β2 | β1A | β2A,  A→α1A | α2A (C) S→β1 | β2, A→α1A | α2A (D) S→β1 | β2 | β1A | β2A,  A→α1A | α2A | λ

Last Answer : (D) S→β1 | β2 | β1A | β2A,  A→α1A | α2A | λ

Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone

Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Last Answer : C. Agonistic action on vascular α2 adrenergic receptors

Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Description : Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Last Answer : D. Constricting cranial vessels and reducing perivascular neurogenic inflammation

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

Norepinephrine binds mainly to (A) α-Adrenergic receptors (B) β-Adrenergic receptrors (C) Muscarinic receptors (D) Nicotinic receptors

Description : Norepinephrine binds mainly to (A) α-Adrenergic receptors (B) β-Adrenergic receptrors (C) Muscarinic receptors (D) Nicotinic receptors

Last Answer : Answer : A

Tyrosine kinase activity is present in (A) α-Adrenergic receptors (B) β-Adrenergic receptors (C) Cholinergic receptors (D) Insulin receptors

Description : Tyrosine kinase activity is present in (A) α-Adrenergic receptors (B) β-Adrenergic receptors (C) Cholinergic receptors (D) Insulin receptors

Last Answer : Answer : D

Which of the following receptors does not span the cell membrane 7 times a. β-Adrenergic receptor b. Rhodopsin c. 5-HTic receptor d. Mineralocorticoid receptor

Description : Which of the following receptors does not span the cell membrane 7 times a. β-Adrenergic receptor b. Rhodopsin c. 5-HTic receptor d. Mineralocorticoid receptor

Last Answer : Mineralocorticoid receptor

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Description : Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics

Last Answer : D. Diuretics

The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Description : The following is true of propafenone except: A. It is a weak Na+ channel blocker B. It markedly delays recovery of myocardial Na+ channels C. It has additional β-adrenergic blocking property D. It slows anterograde as well as retrograde conduction in the WPW bypass tract

Last Answer : A. It is a weak Na+ channel blocker

The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Description : The following is true of β-adrenergic blocker therapy in CHF: A. They are added to conventional therapy after cardiac compensation is restored B. They are indicated only in severe (NYHA class IV) heart failure C. They are to be used only at low doses D. All of the above

Last Answer : A. They are added to conventional therapy after cardiac compensation is restored

In patients of congestive heart failure, β-adrenergic blockers: A. Are absolutely contraindicated B. Can prolong survival C. Can improve haemodynamics after compensation has been restored D. Both B and C are correct

Description : In patients of congestive heart failure, β-adrenergic blockers: A. Are absolutely contraindicated B. Can prolong survival C. Can improve haemodynamics after compensation has been restored D. Both B and C are correct

Last Answer : D. Both B and C are correct

Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve

Last Answer : C. Do not block any effect of injected adrenaline